查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1511905

美國更年期市場規模、佔有率和趨勢分析報告：按治療方法和細分市場預測，2024-2030 年

U.S. Menopause Market Size, Share & Trends Analysis Report By Treatment (Dietary Supplements, OTC Pharma Products), And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格

美國更年期市場的成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，美國更年期市場規模預計將達到73億美元，預測期內複合年成長率為4.8%。

世界上越來越多的老年女性進入更年期並出現相關症狀，導致對更年期相關產品、服務和治療的需求增加。此外，由於人們越來越偏好天然和有機更年期疾病治療藥物，美國的更年期疾病市場正在擴大。此外，先進產品和技術的引入，例如無激素治療方法和遠端醫療服務，也支持了市場成長。

吸煙、飲酒和肥胖等生活習慣會使更年期症狀惡化，導致更年期治療的需求增加。生活方式不健康的女性可能會出現更嚴重的更年期症狀，預計將推動市場成長。美國國家醫學圖書館發表的一項研究發現，肥胖吸菸者出現更頻繁和更嚴重血管舒縮症狀的風險顯著增加。

個人化醫療根據每位患者的需求提供量身定做的治療，正受到越來越多的關注。例如，2023 年 3 月，密西根州 Blue Cross Blue Shield 和 Blue Care Network 宣布推出女性健康解決方案，以幫助會員度過更年期。家庭建設和婦女健康支持解決方案的一個關鍵功能是提供個人化護理的數位應用程式，使成員能夠識別症狀、探索治療方案、與專家聯繫並參與同伴社區的幫助支持。

美國更年期市場報告亮點

  • 由於更年期自然治療方法和成分的認知度、可用性和價格不斷提高，營養食品將在治療領域佔據主導地位，到 2023 年將佔據約 95% 的銷售佔有率。
  • 對副作用和長期健康風險的擔憂導致女性轉向更年期非荷爾蒙治療，例如草藥補充品、針灸和認知行為療法。
  • 2024 年 1 月，Dr. Reddy's Laboratories Ltd. 從 Amyris, Inc. 收購了 MenoLabs，這是一個針對女性健康的營養食品組合。 美國 Reddy’s 現在擁有全部七種 MenoLabs補充品，包括 MenoGlow、MenoFit 和 Happy Fiber 等益生菌，旨在改善更年期和更年期症狀。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第 3 章美國更年期市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 美國更年期市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章美國更年期市場：治療評估與趨勢分析

  • 2023 年及 2030 年泡沫市場佔有率
  • 細分儀表板
  • 美國更年期市場前景：依治療方法分類
  • 2018-2030年市場規模、預測及趨勢分析

第5章競爭狀況

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商情況
  • 公司簡介
    • Pfizer Inc.
    • Novo Nordisk A/S
    • TherapeuticsMD
    • Bayer AG
    • AbbVie, Inc.
    • Pure Encapsulations, LLC.
    • PADAGIS LLC
Product Code: GVR-4-68040-310-1

U.S. Menopause Market Growth & Trends:

The U.S. menopause market size is anticipated to reach USD 7.3 billion by 2030, growing at a CAGR of 4.8% during the forecast period, according to a new report by Grand View Research, Inc. The rising aging women population worldwide reaching menopause and its related symptoms are resulting in a growing demand for menopause-related products, services, and treatments. In addition, the menopause market in the U.S. is expanding due to the rising inclination towards natural and organic menopause remedies. Furthermore, the market growth is also supported by the introduction of advanced products and technologies, such as hormone-free therapies and telemedicine services.

Lifestyle factors such as smoking, alcohol consumption, and obesity can exacerbate menopause symptoms, leading to an increased demand for menopause treatments. Women who lead unhealthy lifestyles are more likely to experience severe menopause symptoms, which is expected to drive the market's growth. According to a study published by the National Library of Medicine, the risk of frequent or severe vasomotor symptoms increased significantly among obese smokers.

There has been a growing focus on personalized medicine, with treatments tailored to each patient's individual needs However, several smaller companies specialize in niche areas of the market, such as alternative therapies or personalized medicine approaches. For instance, in March 2023, Blue Cross Blue Shield of Michigan and Blue Care Network introduced a women's health solution to aid their members in transitioning into menopause. A key feature of the Family Building and Women's Health Support Solution is a digital app that provides personalized care, helping members identify symptoms, explore treatment options, connect with experts, and join peer communities for support.

U.S. Menopause Market Report Highlights:

  • Dietary supplements dominated the treatment segment with around 95% of the revenue share in 2023, owing to the increasing awareness, availability, and affordability of natural treatments and ingredients during the menopause stage
  • Women are opting for non-hormonal treatments for menopause, such as herbal supplements, acupuncture, and cognitive-behavioral therapy, due to concerns about side effects and long-term health risks
  • In January 2024, Dr. Reddy's Laboratories Ltd. acquired MenoLabs, a portfolio of dietary supplements for women's health, from Amyris, Inc. The U.S. Dr. Reddy's now owns all seven MenoLabs supplements, which are designed to help with symptoms of perimenopause and menopause, including probiotics like MenoGlow, MenoFit, and Happy Fiber.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Volume price analysis (Model 2)
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment outlook
  • 2.3. Competitive Insights

Chapter 3. U.S. Menopause Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market restraint analysis
  • 3.3. U.S. Menopause Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. U.S. Menopause Market: Treatment Estimates & Trend Analysis

  • 4.1. Form Market Share, 2023 & 2030
  • 4.2. Segment Dashboard
  • 4.3. U.S. Menopause Market by Treatment Outlook
  • 4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
    • 4.4.1. Dietary Supplements
      • 4.4.1.1. Market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2. OTC Pharma Products
      • 4.4.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.2. Hormonal
      • 4.4.2.2.1. Market estimates and forecasts 2018 to 2030 (USD Million)
      • 4.4.2.3. Non Hormonal
      • 4.4.2.3.1. Market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Competitive Landscape

  • 5.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 5.2. Company/Competition Categorization
  • 5.3. Vendor Landscape
    • 5.3.1. List of key distributors and channel partners
    • 5.3.2. Key customers
    • 5.3.3. Key company heat map analysis, 2023
  • 5.4. Company Profiles
    • 5.4.1. Pfizer Inc.
      • 5.4.1.1. Company overview
      • 5.4.1.2. Financial performance
      • 5.4.1.3. Product benchmarking
      • 5.4.1.4. Strategic initiatives
    • 5.4.2. Novo Nordisk A/S
      • 5.4.2.1. Company overview
      • 5.4.2.2. Financial performance
      • 5.4.2.3. Product benchmarking
      • 5.4.2.4. Strategic initiatives
    • 5.4.3. TherapeuticsMD
      • 5.4.3.1. Company overview
      • 5.4.3.2. Financial performance
      • 5.4.3.3. Product benchmarking
      • 5.4.3.4. Strategic initiatives
    • 5.4.4. Bayer AG
      • 5.4.4.1. Company overview
      • 5.4.4.2. Financial performance
      • 5.4.4.3. Product benchmarking
      • 5.4.4.4. Strategic initiatives
    • 5.4.5. AbbVie, Inc.
      • 5.4.5.1. Company overview
      • 5.4.5.2. Financial performance
      • 5.4.5.3. Product benchmarking
      • 5.4.5.4. Strategic initiatives
    • 5.4.6. Pure Encapsulations, LLC.
      • 5.4.6.1. Company overview
      • 5.4.6.2. Financial performance
      • 5.4.6.3. Product benchmarking
      • 5.4.6.4. Strategic initiatives
    • 5.4.7. PADAGIS LLC
      • 5.4.7.1. Company overview
      • 5.4.7.2. Financial performance
      • 5.4.7.3. Product benchmarking
      • 5.4.7.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviations
  • Table 2 U.S. Menopause market, by treatment, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 Value-chain-based sizing & forecasting
  • Fig. 6 QFD modeling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 U.S. menopause market: market outlook
  • Fig. 9 U.S. menopause competitive insights
  • Fig. 10 Parent market outlook
  • Fig. 11 Related/ancillary market outlook
  • Fig. 12 Penetration and growth prospect mapping
  • Fig. 13 U.S. menopause market driver impact
  • Fig. 14 U.S. menopause market restraint impact
  • Fig. 15 U.S. menopause market: Treatment movement analysis
  • Fig. 16 U.S. menopause market: Treatment outlook and key takeaways
  • Fig. 17 Dietary supplements market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 OTC pharma products estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Hormonal estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Non hormonal market estimates and forecasts, 2018 - 2030 (USD Million)